STC3141 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This STC3141 Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 14 August 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Executive recommendation: HOLD / OPTION
Decision memo
Preserve optionality until clinical differentiation, transaction economics, and freedom-to-operate are sufficiently de-risked.
The central underwriting question is whether STC3141 can convert its Not disclosed profile and Not disclosed biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | STC3141 (query alias: STC3141) |
|---|---|
| Modality / target | Not disclosed; Not disclosed; Not disclosed |
| Highest global status | Not disclosed |
| Originator | Not disclosed |
| Active developers | Not disclosed |
The MCP disease footprint includes no disclosed indication. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT06548854 | Phase 2 | Active, not recruiting | 180 | Not disclosed |
| NCT04880694 | Phase 2 | Completed | 25 | Not disclosed |
| ACTRN12620000716965 | Phase 1 | Completed | 26 | Not disclosed |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
全球首个！远大医药全球创新产品STC3141中国II期临床研究成功达到临床终点
临床2期; n=180; evaluation: 积极. Reported fields: SOFA(第7天) = 药物治疗组第7天SOFA评分较基线均有明显下降，尤其是高剂量组，降幅明显大于安慰剂组，差异具有统计学显著性和临床意义。 ; SOFA(第7天) = 药物治疗组第7天SOFA评分较基线均有明显下降，尤其是高剂量组，降幅明显大于安慰剂组，差异具有统计学显著性和临床意义。
远大医药全球创新产品STC3141于中国开展的治疗急性呼吸窘迫综合征Ib期临床试验达到临床终点
临床1期; n=16; evaluation: 积极. Reported fields: AE = 总体安全性特征未提示任何潜在严重安全性问题或非预期结果，安全性及耐受性良好
自愿性公告: 本集团全球创新产品STC3141中国开展的治疗急性呼吸窘迫综合征 Ib 期临床试验已完成全部患者入组给药及在欧洲开展的治疗重症COVID-19的IIa期临床试验达到主要临床终点
临床2期; n=25; evaluation: 积极. Reported fields: 不良事件 = 達到了臨床方案預設的主要終點，未發生藥物相關的嚴重不良反應，患者耐受性良好 ; 不良事件 = 達到了臨床方案預設的主要終點，未發生藥物相關的嚴重不良反應，患者耐受性良好
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
STC3141 addresses its disclosed development indications. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Not disclosed—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 0 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| No matched asset transaction returned. | |||
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Class crowding and differentiation versus other PD-(L)1/VEGF agents
- Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
- Biomarker strategy, indication selection, and head-to-head endpoint execution
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
HOLD / OPTION
Preserve optionality until clinical differentiation, transaction economics, and freedom-to-operate are sufficiently de-risked.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 14 August 2026. Counts and status fields may change as source records update.
